Search

Displaying results 2241 - 2250 of 10000 in total
  1. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections. … PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small

    Synonyms: PEG INF alfacon-1, Peginterferon alfacon-1
  2. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.

  3. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  4. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. … AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  5. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

    Synonyms: 1H-PYRAZOLO(3,4-B)PYRIDINE-5-CARBOXYLIC ACID, 1-ETHYL-4-((1-METHYLETHYLIDENE)HYDRAZINO)-, ETHYL ESTERCategories: Heterocyclic Compounds, 1-Ring
  6. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. … This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.

  7. Drug

    HCV-086

    go.drugbank.com/drugs/DB05884
    Experimental

    HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.

  8. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    MAD) Phase I trials. … Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and

  9. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models … It is developed by Insmed and is currently under phase I of the clinical trial.

    Synonyms: rhIGFBP-3
  10. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].

    Categories: Compounds used in a research, industrial, or household setting